Evaluation of MUC1 splice variants as prognostic markers in patients with ductal carcinoma in situ of the breast.
about
Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucinGenetic regulation of MUC1 alternative splicing in human tissuesMUC1/A and MUC1/B splice variants differentially regulate inflammatory cytokine expression
P2860
Evaluation of MUC1 splice variants as prognostic markers in patients with ductal carcinoma in situ of the breast.
description
2003 nî lūn-bûn
@nan
2003 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Evaluation of MUC1 splice vari ...... rcinoma in situ of the breast.
@ast
Evaluation of MUC1 splice vari ...... rcinoma in situ of the breast.
@en
type
label
Evaluation of MUC1 splice vari ...... rcinoma in situ of the breast.
@ast
Evaluation of MUC1 splice vari ...... rcinoma in situ of the breast.
@en
prefLabel
Evaluation of MUC1 splice vari ...... rcinoma in situ of the breast.
@ast
Evaluation of MUC1 splice vari ...... rcinoma in situ of the breast.
@en
P2093
P1433
P1476
Evaluation of MUC1 splice vari ...... arcinoma in situ of the breast
@en
P2093
Gerhild Fabjani
Klaus Kaserer
Magarethe Rudas
Paul Speiser
Sepp Leodolter
P304
P577
2003-11-01T00:00:00Z